Broad Clinical Labs Teams Up with Genomes2Veterans
Broad Clinical Labs (BCL) has announced an important partnership with the Genomes2Veterans (G2V) Research Program. This collaboration focuses on a significant clinical trial funded by the Department of Veterans Affairs, dedicated to improving approaches to prostate cancer assessment and prevention. The trial is officially called the Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS), and it marks a pivotal moment in personalized medicine, particularly for veterans.
Precision Medicine in Action
The essence of modern healthcare is rapidly shifting towards personalized solutions, and understanding the genetic risk associated with diseases like prostate cancer plays a critical role in this transition. By utilizing resources from the Veterans Affairs’ Million Veteran Program (MVP), researchers have developed a revolutionary genomic risk model known as the Prostate CAncer integrated Risk Evaluation (P-CARE). This model is based on extensive data collected from over 585,000 male participants, including a significant representation of Black or African American individuals.
P-CARE integrates genetic scores, family medical history, and individual genetic background, creating a detailed risk assessment for prostate cancer. This thorough model has been validated with success in various datasets, including those from renowned research consortia. It is now positioned to be utilized in the ProGRESS clinical trial, aiming to enhance screening accuracy for prostate cancer.
Transforming Screening Recommendations
Findings from recent studies reveal that P-CARE illustrates crucial risk gradients for prostate cancer. Participants scoring in the top 20% exhibit a dramatically elevated likelihood of developing the disease. To provide context, individuals in the MVP group with high P-CARE scores are 2.75 times more likely to develop any form of prostate cancer. Alarmingly, the possibility of developing metastatic prostate cancer is 2.78 times higher, while the risk of fatal prostate cancer is 2.59 times greater when compared to those with median scores.
Insights for Healthcare Providers
The implications of these findings are profound. Among those identified as high-risk, nearly half could develop prostate cancer by age 90, compared to just 14% of those deemed low-risk. The ProGRESS trial will assess whether this information can empower healthcare providers to tailor their screening recommendations more effectively, ensuring that men at varying risk levels receive appropriate guidance and intervention.
Leveraging the Power of Veteran Data
Dr. Jason Vassy, a clinician-investigator at the Veterans Affairs Boston Healthcare System, emphasizes the benefits of leveraging biobank-linked healthcare systems. This innovative approach provides a unique opportunity to harness existing patient data for enhancing healthcare models, ultimately benefiting veterans. His enthusiasm for the ProGRESS trial reflects the hope that precision prostate cancer screening can lead to improved health outcomes for participants.
Innovative Technology and Support
Broad Clinical Labs prides itself on being at the forefront of genomic technology. According to Dr. Niall Lennon, CSO and chair of Broad Clinical Labs, their Blended Genome-Exome platform empowers the trial with its ability to calculate polygenic scores and identify monogenic risk factors. This state-of-the-art approach allows the researchers to validate and launch a new pipeline for assessing genomic risk effectively.
The Path Forward
The ProGRESS trial highlights the necessity for expedited translation of research into concrete, real-world applications. Veteran candidates aged between 55-69, who regularly receive care from Veterans Affairs and have no personal history of prostate cancer, are invited to participate in this groundbreaking study. More details can be found through ClinicalTrials.gov by searching for Trial ID NCT05926102.
Frequently Asked Questions
What is the ProGRESS trial?
The ProGRESS trial is a clinical study aimed at refining prostate cancer screening approaches by using genetic risk assessments from the P-CARE model.
Who is eligible to participate in the study?
Veterans aged 55-69 who receive regular care from Veterans Affairs and lack a personal history of prostate cancer can enroll.
How does the P-CARE model work?
The P-CARE model utilizes genetic scores, family history, and genetic background to evaluate individual risk for prostate cancer.
What are the expected outcomes of the trial?
The trial aims to determine whether enhanced genetic risk information can improve screening recommendations and health outcomes for veterans.
Who are the key participants in this collaboration?
This initiative involves Broad Clinical Labs and Genomes2Veterans, along with the support of the Department of Veterans Affairs.
